Innovative Therapies for Complex Diseases
Repligen's Development Pipeline

Repligen is developing a pipeline of innovative products and therapies with the potential to make a significant impact in the lives of patients suffering from diseases with limited treatment options. The company's diverse pipeline includes the following development programs:

• RG1068, synthetic human secretin, in Phase 3 development to improve magnetic resonance imaging of the pancreas
• RG2417, an oral formulation of uridine, in Phase 2b development for treatment of acute depression in bipolar disorder
• RG2833, HDAC-3 inhibitors in preclinical development for Friedreich's ataxia
• RG3039, promoters of SMN2 gene expression for spinal muscular atrophy

Whether addressing a large disease area such as bipolar disorder, or a smaller "orphan" patient population such as Friedreich's ataxia, Repligen's programs target novel biological pathways and have the potential to dramatically alter the course of disease.

For more information on a particular product candidate or indication, please click on the corresponding product name in the chart above.